This HTML5 document contains 103 embedded RDF statements represented using HTML+Microdata notation.

The embedded RDF content will be recognized by any processor of HTML5 Microdata.

Namespace Prefixes

PrefixIRI
n11http://linked.opendata.cz/resource/drugbank/drug/DB01195/identifier/drugbank/
n2http://linked.opendata.cz/resource/drugbank/drug/
dctermshttp://purl.org/dc/terms/
n13http://linked.opendata.cz/resource/drugbank/drug/DB01195/identifier/iuphar/
n32http://linked.opendata.cz/resource/AHFS/
foafhttp://xmlns.com/foaf/0.1/
n27http://linked.opendata.cz/resource/drugbank/company/
n31http://linked.opendata.cz/resource/mesh/concept/
n15http://linked.opendata.cz/resource/drugbank/drug/DB01195/identifier/guide-to-pharmacology/
n19http://linked.opendata.cz/resource/drugbank/drug/DB01195/identifier/national-drug-code-directory/
n5http://linked.opendata.cz/resource/drugbank/dosage/
n26http://bio2rdf.org/drugbank:
n10http://linked.opendata.cz/resource/drugbank/drug/DB01195/identifier/chemspider/
admshttp://www.w3.org/ns/adms#
n25http://wifo5-03.informatik.uni-mannheim.de/drugbank/resource/drugs/
n7http://linked.opendata.cz/resource/drugbank/drug/DB01195/identifier/wikipedia/
n16http://linked.opendata.cz/resource/drugbank/drug/DB01195/identifier/pharmgkb/
rdfhttp://www.w3.org/1999/02/22-rdf-syntax-ns#
n28http://linked.opendata.cz/resource/drugbank/medicinal-product/
owlhttp://www.w3.org/2002/07/owl#
n30http://linked.opendata.cz/ontology/mesh/
n3http://linked.opendata.cz/ontology/drugbank/
n29http://www.drugs.com/cdi/
n12http://linked.opendata.cz/resource/drugbank/drug/DB01195/identifier/bindingdb/
n14http://linked.opendata.cz/resource/drugbank/drug/DB01195/identifier/kegg-compound/
n22http://www.rxlist.com/cgi/generic2/
n4http://linked.opendata.cz/resource/drugbank/property/
n17http://linked.opendata.cz/resource/drugbank/drug/DB01195/identifier/pubchem-compound/
xsdhhttp://www.w3.org/2001/XMLSchema#
n9http://linked.opendata.cz/resource/atc/
n18http://linked.opendata.cz/resource/drugbank/drug/DB01195/identifier/kegg-drug/
n20http://linked.opendata.cz/resource/drugbank/drug/DB01195/identifier/pubchem-substance/
n8http://linked.opendata.cz/ontology/sukl/drug/

Statements

Subject Item
n2:DB01195
rdf:type
n3:Drug
n3:description
A potent anti-arrhythmia agent, effective in a wide range of ventricular and atrial arrhythmias and tachycardias. Paradoxically, however, in myocardial infarct patients with either symptomatic or asymptomatic arrhythmia, flecainide exacerbates the arrhythmia and is not recommended for use in these patients. [PubChem]
n3:dosage
n5:271B533F-363D-11E5-9242-09173F13E4C5 n5:271B5340-363D-11E5-9242-09173F13E4C5 n5:271B5341-363D-11E5-9242-09173F13E4C5
n3:generalReferences
# Gill JS, Mehta D, Ward DE, Camm AJ: Efficacy of flecainide, sotalol, and verapamil in the treatment of right ventricular tachycardia in patients without overt cardiac abnormality. Br Heart J. 1992 Oct;68(4):392-7. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/1449923 # Sakurada H, Hiyoshi Y, Tejima T, Yanase O, Tokuyasu Y, Watanabe K, Motomiya T, Sugiura M, Hiraoka M: [Effects of oral flecainide treatment of refractory tachyarrhythmias] Kokyu To Junkan. 1990 May;38(5):471-6. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/2115193 # Echt DS, Liebson PR, Mitchell LB, Peters RW, Obias-Manno D, Barker AH, Arensberg D, Baker A, Friedman L, Greene HL, et al.: Mortality and morbidity in patients receiving encainide, flecainide, or placebo. The Cardiac Arrhythmia Suppression Trial. N Engl J Med. 1991 Mar 21;324(12):781-8. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/1900101 # Greenberg HM, Dwyer EM Jr, Hochman JS, Steinberg JS, Echt DS, Peters RW: Interaction of ischaemia and encainide/flecainide treatment: a proposed mechanism for the increased mortality in CAST I. Br Heart J. 1995 Dec;74(6):631-5. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/8541168 # Gasparini M, Priori SG, Mantica M, Napolitano C, Galimberti P, Ceriotti C, Simonini S: Flecainide test in Brugada syndrome: a reproducible but risky tool. Pacing Clin Electrophysiol. 2003 Jan;26(1 Pt 2):338-41. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/12687841
n3:group
approved withdrawn
n3:halfLife
20 hours (range 12-27 hours)
n3:indication
Flecainide is is a class Ic antiarrhythmic agent and as such, it is used for the prevention of paroxysmal supraventricular tachycardias (PSVT), including atrioventricular nodal reentrant tachycardia, atrioventricular reentrant tachycardia and other supraventricular tachycardias of unspecified mechanism associated with disablin.
owl:sameAs
n25:DB01195 n26:DB01195
dcterms:title
Flecainide
adms:identifier
n7:Flecainide n10:3239 n11:DB01195 n12:50131434 n13:2560 n14:C07001 n15:2560 n16:PA449646 n17:3356 n18:D07962 n19:0089-0305-10 n20:46508078
n3:mechanismOfAction
Flecainide acts on sodium channels on the neuronal cell membrane, limiting the spread of seizure activity and reducing seizure propagation. The antiarrhythmic actions are mediated through effects on sodium channels in Purkinje fibers. Flecainide is a sodium channel blocker, binding to voltage gated sodium channels. It stabilizes the neuronal membrane by inhibiting the ionic fluxes required for the initiation and conduction of impulses. Ventricular excitability is depressed and the stimulation threshold of the ventricle is increased during diastole.
n3:packager
n27:271B5334-363D-11E5-9242-09173F13E4C5 n27:271B5332-363D-11E5-9242-09173F13E4C5 n27:271B5333-363D-11E5-9242-09173F13E4C5 n27:271B5330-363D-11E5-9242-09173F13E4C5 n27:271B5331-363D-11E5-9242-09173F13E4C5 n27:271B532E-363D-11E5-9242-09173F13E4C5 n27:271B532F-363D-11E5-9242-09173F13E4C5 n27:271B532C-363D-11E5-9242-09173F13E4C5 n27:271B532D-363D-11E5-9242-09173F13E4C5 n27:271B532A-363D-11E5-9242-09173F13E4C5 n27:271B532B-363D-11E5-9242-09173F13E4C5 n27:271B5328-363D-11E5-9242-09173F13E4C5 n27:271B5329-363D-11E5-9242-09173F13E4C5 n27:271B5326-363D-11E5-9242-09173F13E4C5 n27:271B5327-363D-11E5-9242-09173F13E4C5 n27:271B5325-363D-11E5-9242-09173F13E4C5
n3:routeOfElimination
In healthy subjects, about 30% of a single oral dose (range, 10 to 50%) is excreted in urine as unchanged drug. Several minor metabolites (3% of the dose or less) are also found in urine; only 5% of an oral dose is excreted in feces. In patients, free (unconjugated) plasma levels of the two major metabolites are very low (less than 0.05 μg/mL).
n3:synonym
CCRIS 313 Flecainida Flecaine (+-)-Flecainide Flecainidum N-(2-Piperidinylmethyl)-2,5-bis(2,2,2-trifluoroethoxy)benzamide
n3:toxicity
Oral LD50 is 50-498 mg/kg in rat. Symptoms of overdose include nausea and vomiting, convulsions, hypotension, bradycardia, syncope, extreme widening of the QRS complex, widening of the QT interval, widening of the PR interval, ventricular tachycardia, AV nodal block, asystole, bundle branch block, cardiac failure, and cardiac arrest.
n8:hasAHFSCode
n32:24-04-04-12
n3:foodInteraction
Take without regard to meals.
n3:proteinBinding
40%
n3:salt
n3:synthesisReference
Bmitt, E.H. and Brown, W.R.; U.S. Patent 3,900,481; August 19,1975; assigned to Riker Laboratories, Inc.
n30:hasConcept
n31:M0008556
foaf:page
n22:flecainide.htm n29:flecainide.html
n3:IUPAC-Name
n4:271B5346-363D-11E5-9242-09173F13E4C5
n3:InChI
n4:271B534C-363D-11E5-9242-09173F13E4C5
n3:Molecular-Formula
n4:271B534B-363D-11E5-9242-09173F13E4C5
n3:Molecular-Weight
n4:271B5348-363D-11E5-9242-09173F13E4C5
n3:Monoisotopic-Weight
n4:271B5349-363D-11E5-9242-09173F13E4C5
n3:SMILES
n4:271B534A-363D-11E5-9242-09173F13E4C5
n3:Water-Solubility
n4:271B5344-363D-11E5-9242-09173F13E4C5 n4:271B535C-363D-11E5-9242-09173F13E4C5
n3:logP
n4:271B5342-363D-11E5-9242-09173F13E4C5 n4:271B5345-363D-11E5-9242-09173F13E4C5 n4:271B535E-363D-11E5-9242-09173F13E4C5
n3:logS
n4:271B5343-363D-11E5-9242-09173F13E4C5
n3:pKa
n4:271B535F-363D-11E5-9242-09173F13E4C5
n8:hasATCCode
n9:C01BC04
n3:H-Bond-Acceptor-Count
n4:271B5352-363D-11E5-9242-09173F13E4C5
n3:H-Bond-Donor-Count
n4:271B5353-363D-11E5-9242-09173F13E4C5
n3:InChIKey
n4:271B534D-363D-11E5-9242-09173F13E4C5
n3:Polar-Surface-Area--PSA-
n4:271B534E-363D-11E5-9242-09173F13E4C5
n3:Polarizability
n4:271B5350-363D-11E5-9242-09173F13E4C5
n3:Refractivity
n4:271B534F-363D-11E5-9242-09173F13E4C5
n3:Rotatable-Bond-Count
n4:271B5351-363D-11E5-9242-09173F13E4C5
n3:absorption
Nearly complete following oral administration.
n3:affectedOrganism
Humans and other mammals
n3:casRegistryNumber
54143-55-4
n3:category
n3:containedIn
n28:271B533D-363D-11E5-9242-09173F13E4C5 n28:271B533E-363D-11E5-9242-09173F13E4C5 n28:271B533B-363D-11E5-9242-09173F13E4C5 n28:271B533C-363D-11E5-9242-09173F13E4C5 n28:271B5339-363D-11E5-9242-09173F13E4C5 n28:271B533A-363D-11E5-9242-09173F13E4C5 n28:271B5337-363D-11E5-9242-09173F13E4C5 n28:271B5338-363D-11E5-9242-09173F13E4C5 n28:271B5335-363D-11E5-9242-09173F13E4C5 n28:271B5336-363D-11E5-9242-09173F13E4C5
n3:Bioavailability
n4:271B5358-363D-11E5-9242-09173F13E4C5
n3:Ghose-Filter
n4:271B535A-363D-11E5-9242-09173F13E4C5
n3:MDDR-Like-Rule
n4:271B535B-363D-11E5-9242-09173F13E4C5
n3:Melting-Point
n4:271B535D-363D-11E5-9242-09173F13E4C5
n3:Number-of-Rings
n4:271B5357-363D-11E5-9242-09173F13E4C5
n3:Physiological-Charge
n4:271B5356-363D-11E5-9242-09173F13E4C5
n3:Rule-of-Five
n4:271B5359-363D-11E5-9242-09173F13E4C5
n3:Traditional-IUPAC-Name
n4:271B5347-363D-11E5-9242-09173F13E4C5
n3:pKa--strongest-acidic-
n4:271B5354-363D-11E5-9242-09173F13E4C5
n3:pKa--strongest-basic-
n4:271B5355-363D-11E5-9242-09173F13E4C5